Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $542 to $560.